Related Experiment Videos
Lenalidomide therapy for metastatic renal cell carcinoma
Robert J Amato1, Joan Hernandez-McClain, Somyata Saxena
1Genitourinary Oncology Program, Methodist Hospital Research Institute, Houston, TX 77030, USA. ramato@tmh.tmc.edu
American Journal of Clinical Oncology
|June 6, 2008
Summary
Oral lenalidomide shows promise as a safe and effective treatment for patients with refractory metastatic renal cell cancer (RCC). This study indicates lenalidomide can be a valuable option for advanced RCC, warranting further investigation.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Metastatic renal cell cancer (RCC) presents limited treatment options for refractory cases.
- Lenalidomide, an immunomodulatory and antiangiogenic agent, offers a potential therapeutic avenue.
Purpose of the Study:
- To evaluate the safety and efficacy of oral lenalidomide in patients with refractory metastatic RCC.
- To determine tumor response rates, progression-free survival, and overall survival.
Main Methods:
- An open-label, single-center phase II trial was conducted.
- 40 adult patients with newly diagnosed RCC received oral lenalidomide (25 mg/d) for 21 days on/7 days off cycles.
- Primary endpoint was tumor response rate; secondary endpoints included survival and safety.
Main Results:
- 97% of patients were evaluable for response, with a majority having clear cell histotype and prior treatments.
- Tumor response included complete response (3%), partial response (8%), and stable disease (53%).
- Median overall survival was 17 months, with fatigue and neutropenia as common adverse events.
Conclusions:
- Oral lenalidomide demonstrates safety and efficacy in treating refractory metastatic RCC.
- Lenalidomide represents a viable therapeutic option for this patient population.
- Further clinical studies are recommended to confirm these findings.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...